- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05259631
Sedação inalatória (sevoflurano) versus intravenosa (propofol) em adultos com uma forma moderada de SDRA
Sedação inalatória (sevoflurano) versus intravenosa (propofol) em adultos com uma forma moderada de SDRA: um estudo piloto randomizado multicentral
The American European Consensus Conference (AECC) 1994 defined acute respiratory distress syndrome (ARDS) as an acute inflammatory syndrome manifesting as diffuse pulmonary edema and respiratory failure that cannot be explained by, but may co-exist with, left-sided heart failure. During the sequel Conference of the European Society of Intensive Care Medicine, in 2012 minor changes were made, and since that so-called Berlin definition of ARDS is used worldwide for the description of this severe disease. Three grades of severity were proposed to distinguish ARDS according to the level of hypoxemia with a mortality of 24% in patients with mild ARDS, rising to 48% in those with severe ones.
Systemic inflammation is considered to be the main reason of ARDS. Activated neutrophils interact with the alveolar-capillary membrane causing the increasing permeability with the sequence lung edema's development. Inflammatory exudate inactivates surfactant leading to collapse and consolidation of distal airspaces with progressive loss of the lung's gas exchange surface area. Unfortunately, systemic inflammatory response syndrome (SIRS) simultaneously inhibits the mechanism of active pulmonary vasoconstriction and allows deoxygenated blood to pass through unventilated areas of the lung boosting the right-to-left shunt. Both mechanisms lead to hypoxemia, which is the main and obligatory feature of ARDS.
Actually, endothelial dysfunction and transcapillary leakage seem to be one of the main steps in the development of respiratory failure during ARDS. Last decades it was found out that glycocalyx is also participating in this process too.
Thus, it became clear that substances preserving endothelium and glycocalyx from SIRS-causing damage may have a beneficial effect in ARDS treatment. It seems to be crucially important so as the majority of drugs failed to demonstrate any positive effects in terms of ARDS treatment.
To the moment we have some evidence, which came from experimental studies, that halogenated anesthetics can preserve glycocalyx against ischemia-reperfusion injury.
The primary objective for the multicentral INVERSE Trial will be to determine the effects of inhalational (sevoflurane) versus intravenous (propofol) sedation on P/F ratio on the second day, hospital mortality and ICU (intensive care unit), and in-hospital length of stay in adults with a moderate form of ARDS.
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Moscow, Rússia
- Demikhov Municipal Clinical Hospital 68
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age > 18
- Endotracheal intubation or tracheostomy
- Timing: Acute onset of new or worsening of chronic respiratory symptoms within 72 hours before the randomization
- Chest imaging: Bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules
- Origin of edema: Respiratory failure not fully explained by cardiac failure or fluid overload
- Oxygenation: 100 mm Hg < PaO2/FiO2 ≤ 200 mm Hg with PEEP ≥ 5 cm H2O
Exclusion Criteria:
- History or family history of malignant hyperthermia
- History of propofol infusion syndrome
- Documented or suspected increased intracranial pressure
- Chronic restrictive pulmonary disease
- Chronic obstructive pulmonary disease
- Neuromuscular disease
- Chest wall disorder
- Pulmonary vascular disease
- NYHA class ≥ 3
- Severe pulmonary hypertension (mean pulmonary artery pressure > 40 mmHg)
- Documented ongoing COVID-19 infection
- Ongoing immunosuppressive therapy
- Previous randomization in this trial
- Post randomization exclusion criterion: Documented ongoing COVID-19 infection during the first 48 hours after the randomization
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Inhalational sedation
|
Patients are to be sedated by sevoflurane inhalation. For this purpose, any certificated devices are suitable - AnaConDa or Mirus evenly. Starting dose of sevoflurane is to be 2 ml/h and may be modified at the discretion of the attending intensivist to achieve and maintain the target level of sedation |
|
Comparador Ativo: Intravenous sedation
|
Patients of this group will receive an intravenous infusion of propofol with starting dose of 1 mg/kg/h. The precise dose to maintain the desired level of sedation is left at the discretion of the attending intensivist and may be revised at any time. The upper dose limit for propofol is 4 mg/kg/h. In case of tolerance to propofol infusion, midazolam or antipsychotics (haloperidol) can be added to achieve the desired level of sedation |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
P/F ratio
Prazo: day 2 after the randomization
|
PaO2 divided on FiO2 |
day 2 after the randomization
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
28-days mortality
Prazo: 28 day
|
number of deaths |
28 day
|
|
6-months mortality
Prazo: 6 months
|
number of deaths |
6 months
|
|
1-year mortality
Prazo: 1 year
|
number of death |
1 year
|
|
Length of stay in the intensive care unit
Prazo: 1 year
|
number of days in the intensive care unit |
1 year
|
|
Length of hospitalization
Prazo: 1 year
|
number of days in hospital |
1 year
|
|
Ventilator free days in ICU
Prazo: 1 year
|
number of days in ICU - number of days on mechanical ventilation |
1 year
|
|
Ventilator free days during hospitalization
Prazo: 1 year
|
Length of hospitalization - number of days on mechanical ventilation |
1 year
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Valery Likhvantsev, Negovsky Reanimatology Research Institute
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças Respiratórias
- Doenças pulmonares
- Distúrbios Respiratórios
- Síndrome do Desconforto Respiratório
- Produtos químicos orgânicos
- Éteres
- Hidrocarbonetos
- Hidrocarbonetos, cíclicos
- Hidrocarbonetos, aromáticos
- Fenóis
- Derivados de benzeno
- Hidrocarbonetos, halogenados
- Hidrocarbonetos, fluorados
- Éteres de metila
- Sevoflurano
- Propofol
Outros números de identificação do estudo
- INVERSE
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .